Deucravacitinib (Sotyktu™) for plaque psoriasis

STRUCTURE: Deucravacitinib is a small molecule, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2). The inhibitor binds the pseudokinase domain of TYK2 and, via, a conformational change, locks the kinase in its inactive state. Deucravacitinib is an amide-substituted heterocyclic compound with a trideuteromethyl group, a cyclopropane group, a methoxy group, and a methyl-triazole group, with the molecular formula C20H22N8O3.